Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03038672 · OUTCOME

Progression Free Survival (PFS)

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas · Source last updated 2026-05-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
37 months

What was measured

The distribution of PFS will be estimated using the method of Kaplan-Meier. The comparison of progression-free survival between two treatment arms will be based on the log-rank test.

Analysis population: All eligible and treated patients that had a disease evaluation.

Groups in this outcome

Group I (Nivolumab)

Patients receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may cross over to Group II at the time of disease progression.

Group II (Varlilumab, Nivolumab)

Patients receive varlilumab IV over 90 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Group I (Nivolumab)25
Group II (Varlilumab, Nivolumab)24

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Group I (Nivolumab)2.6Not reported1.53.2Not reported
Group II (Varlilumab, Nivolumab)1.5Not reported1.13.2Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.5
        upper Limit
        3.2
        value
        2.6
      2. group Id
        OG001
        lower Limit
        1.1
        upper Limit
        3.2
        value
        1.5
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    2. group Id
      OG001
      value
      24
    units
    Participants
description
The distribution of PFS will be estimated using the method of Kaplan-Meier. The comparison of progression-free survival between two treatment arms will be based on the log-rank test.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may cross over to Group II at the time of disease progression.
    id
    OG000
    title
    Group I (Nivolumab)
  2. description
    Patients receive varlilumab IV over 90 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity.
    id
    OG001
    title
    Group II (Varlilumab, Nivolumab)
param Type
MEAN
population Description
All eligible and treated patients that had a disease evaluation.
reporting Status
POSTED
time Frame
37 months
title
Progression Free Survival (PFS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice